WSE:BML

Stock Analysis Report

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek

Executive Summary

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.

Risk Analysis

Earnings have declined by -8.75% per year over past 5 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (PLN69M)



Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BML has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.4%

BML

-1.5%

PL Biotechs

-0.09%

PL Market


1 Year Return

21.9%

BML

-13.3%

PL Biotechs

-7.7%

PL Market

Return vs Industry: BML exceeded the Polish Biotechs industry which returned -13.3% over the past year.

Return vs Market: BML exceeded the Polish Market which returned -7.6% over the past year.


Shareholder returns

BMLIndustryMarket
7 Day-1.4%-1.5%-0.09%
30 Day4.3%-8.2%-1.8%
90 Day9.6%-7.7%-1.0%
1 Year21.9%21.9%-13.1%-13.3%-4.9%-7.7%
3 Year4.3%4.3%-41.9%-42.0%-4.4%-11.2%
5 Year-73.7%-73.7%-40.3%-41.5%3.0%-10.0%

Price Volatility Vs. Market

How volatile is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek undervalued compared to its fair value and its price relative to the market?

2.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: BML (PLN1.09) is trading above our estimate of fair value (PLN0.33)

Significantly Below Fair Value: BML is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BML is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BML is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BML's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BML is good value based on its PB Ratio (2.2x) compared to the PL Biotechs industry average (2.5x).


Next Steps

Future Growth

How is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek performed over the past 5 years?

-8.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BML is currently unprofitable.

Growing Profit Margin: BML is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BML is unprofitable, and losses have increased over the past 5 years at a rate of -8.8% per year.

Accelerating Growth: Unable to compare BML's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BML is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: BML has a negative Return on Equity (-93.73%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's financial position?


Financial Position Analysis

Short Term Liabilities: BML's short term assets (PLN15.4M) do not cover its short term liabilities (PLN21.0M).

Long Term Liabilities: BML's short term assets (PLN15.4M) do not cover its long term liabilities (PLN31.0M).


Debt to Equity History and Analysis

Debt Level: BML's debt to equity ratio (22.3%) is considered satisfactory.

Reducing Debt: BML's debt to equity ratio has reduced from 28.7% to 22.3% over the past 5 years.


Balance Sheet

Inventory Level: BML has a high level of physical assets or inventory.

Debt Coverage by Assets: BML's debt is covered by short term assets (assets are 2.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BML has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BML is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.6% per year.


Next Steps

Dividend

What is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%6.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BML's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BML's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BML's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BML's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BML's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

zł300k

CEO Compensation


CEO

Marcin Piróg 0

zł300,000

Compensation

Mr. Marcin Piotr Piróg serves as Chief Executive Officer and President of Management Board of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Spólka Akcyjna. Mr. Piróg served as the President of LOT Polish A ...


CEO Compensation Analysis

Compensation vs Market: Marcin's total compensation ($USD76.61K) is below average for companies of similar size in the Polish market ($USD157.18K).

Compensation vs Earnings: Marcin's compensation has increased whilst the company is unprofitable.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
  • Ticker: BML
  • Exchange: WSE
  • Founded: 1944
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł68.798m
  • Shares outstanding: 62.26m
  • Website: https://biomedlublin.com

Location

  • BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
  • ul. Uniwersytecka 10
  • Lublin
  • 20-029
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMLWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNJul 2011
0RKMLSE (London Stock Exchange)YesCommon Bearer SharesGBPLNJul 2011

Biography

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 and Gamma anty-HBs 1000 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker’s fluid, Eagle 1959 medium, RPMI 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was founded in 1944 and is based in Lublin, Poland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/15 22:34
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.